AIROS Medical Appoints Dr. John Evans as Lead Medical Advisor
"
ARTAIRA is a non-invasive intermittent pneumatic compression device cleared by the U.S. Food and Drug Administration (FDA) to increase circulation. The device delivers rapid, high-pressure compression cycles to the calf, ankle and foot to increase blood flow to the legs, feet, and toes. Patients with a prescription can use the device at home. ARTAIRA is available throughout
About Dr.
About AIROS Medical, Inc.
AIROS® Medical, Inc. is a medical technology manufacturer and designer specializing in compression therapy systems that treat peripheral vascular disorders. The company's product line includes various pneumatic compression devices and garments. The AIROS 6P and AIROS 8P compression devices treat lower extremity, upper extremity, and truncal lymphedema as well as chronic venous insufficiency (CVI). The ARTAIRA® arterial compression device treats intermittent claudication, rest pain, diabetic foot and arterial ulcers, and ischemia. The company's team of engineers, regulatory experts, and clinical partners are dedicated to creating medical devices that improve quality of life for patients. AIROS Medical was founded in 2016 and is headquartered in
Contact:
Marketing Manager
+12155892656
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/airos-medical-appoints-dr-john-evans-as-lead-medical-advisor-302730158.html
SOURCE AIROS Medical
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Curitics Health Unveils Next-Generation AI Platform to Transform Clinical Workflows
- Magnetic Money Secrets Announces the Launch of a 14-Day Audio Experience Designed to Reshape Financial Mindsets
- DOCOMO to End the "MANGA MIRAI" Digital Comic Distribution Service and Migrate Purchased Titles to "MangaPlaza"
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
AdCom, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share